Sign Out
Probenecid competes with Meropenem for active tubular secretion and thus inhibits the renal excretion of Meropenem with the effect of increasing the elimination half-life and plasma concentration of Meropenem. As the potency and duration of action of Meropenem dosed without probenecid are adequate the co-administration of probenecid with Meropenem is not recommended. The potential effect of Meropenem on the protein binding of other medicines or metabolism has not been studied. However, the protein binding is so low (approximately 2%) that no interactions with other compounds would be expected on the basis of this mechanism.
Meropenem has been administered concomitantly with many other medications without apparent adverse interaction.
Meropenem FOR INJECTION USP may reduce serum valproic acid levels.
Subtherapeutic levels may be reached in some patients. However, no specific drug interaction studies other than with probenecid were conducted.
Continue with Google